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Abstract
The Brazilian Diabetes Society is starting an innovative project of quantitative assessment of medical arguments of and 
implementing a new way of elaborating SBD Position Statements. The final aim of this particular project is to propose a 
new Brazilian algorithm for the treatment of type 2 diabetes, based on the opinions of endocrinologists surveyed from 
a poll conducted on the Brazilian Diabetes Society website regarding the latest algorithm proposed by American 
Diabetes Association /European Association for the Study of Diabetes, published in January 2009.
An additional source used, as a basis for the new algorithm, was to assess the acceptability of controversial arguments 
published in international literature, through a panel of renowned Brazilian specialists. Thirty controversial arguments 
in diabetes have been selected with their respective references, where each argument was assessed and scored 
according to its acceptability level and personal conviction of each member of the evaluation panel.
This methodology was adapted using a similar approach to the one adopted in the recent position statement by the 
American College of Cardiology on coronary revascularization, of which not only cardiologists took part, but also 
specialists of other related areas.
Module 1
Summary of Brazilian Diabets Society Members Opinions 
on the New ADA/EASD Algorithm
Considering the great controversy raised by the recom-
mendations at the recent ADA/EASD algorithm, the Bra-
zilian Diabetes Society (BDS) decided to evaluate the
opinions of its members, through a survey conducted on
the BDS' website during ten days, in November 2008
[1,2]. Two hundred and seventeen associates (endocrinol-
ogists) completed this survey.
Table 1 shows the percentages of answers to the pro-
posed questions to BDS' associates.
General conclusions about the survey results
The results showed that the majority of the brazilian
endocrinologists do not agree with the guidelines pro-
posed by the ADA/EASD algorithm regarding the use of
glitazone, GLP-1 analogs and DPP-IV inhibitors in the
treatment of Type 2 Diabetes.
Considering the need for an algorithm reflecting the
opinion of Brazilian endocrinologists, the Brazilian Dia-
betes Society decided to develop this position statement,
whose recommendations shall be dictated by the techni-
cal panel assessments, named by the entity and also by
the results obtained from the survey.
Module 2
Results of the controversial diabetes argument 
acceptability assessment
In addition to the feedback from associates obtained
through the survey and in order to provide a more robust
basis to the algorithm proposed for the treatment of type
2 diabetes, the Brazilian Diabetes Society obtained the
opinions of a panel formed by renowned Brazilian spe-
cialists regarding recommendations, guidelines and con-
troversial arguments on the treatment of type 2 diabetes
in international literature.
Thirty controversial arguments were individually
assessed and scored on a 10-point scale by the evaluation
panel members, who assigned individual scores (0-10) to
the 30 arguments presented, which were made into 5
acceptability levels (1-5).
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Page 2 of 9The correlation between scores and their correspond-
ing acceptability levels, as well as the analytical interpre-
tation of results, are summarized in table 2.
Average acceptability level of controversial matters assessed 
and their respective bibliographical references
Table S1, Additional file 1 shows the relation between
controversial matters assessed and their respective biblio-
graphical references and the average level of acceptability
for each controversial matter, following the calculation
methodology as defined in the previous item.
Module 3
New SBD algorithm proposal for the treatment of type 2 
diabetes
Laboratory goals for characterization of good glycemic 
control
The desirable goal for A1C, as defined by the previous
position statement in 2007, recommended A1C levels <
6.5%. In this new Position Statement, the recommended
A1C goal was redefined to <7.0% as shown in table 3.
However, according to the ADA's 2010 statement, in
patients with a history of severe hypoglycemia, patients
with limited life expectancies, children, individuals with
comorbidities, those with longstanding diabetes,
advanced age and those with advanced microvascular or
macrovascular complications" intensive glycemic control
may outweigh its benefits. But for patients with short
duration of diabetes, long life expectancy, and no signifi-
cant CVD a level of A1c even lower than the general goal
of <7%, has been suggested if this can be achieved with-
out significant hypoglycemia or other adverse effects [3-
5].
Regarding tolerable levels for laboratory goals, they
were defined based on the recommendations contained
in the bibliographical references [3-5].
Table 1: Percentuals of answers to the proposed questions
ANSWERES' PERCENTAGES
PROPOSED QUESTIONS Yes No Others
1. Have you read the Treatment of Type 2 Diabetes algorithm proposed by ADA/EASD? 90 10 -
2. Were you aware that the document expresses the opinion of a few authors and not of the entities 
involved?
77 23 -
3. Do you intend to adopt the stages and steps suggested by this algorithm in your practice? 51 49 -
4. Do you think that rosiglitazone-associated adverse events have been ratified in the medical literature of 
excellence?
36 64 -
5. Do you think that the cardiovascular protection assigned topioglitazone in that Position Statement is 
real?
34 66 -
6. Do you think that glitazone-associated adverse events (bone fracture and cardiovascular events) are 
effects pertaining to this therapeutical class?
49 21 30
7. Do you think that only GLP-1 analogs should be included in diabetes treatment excluding DPP-4 
inhibitors?
13 69 18
8. Do you think that BDS' members have the expertise and the ability of criticism to issue a Position 
Statement about this Algorithm?
87 4 9
Gomes MB. Enquete sobre Algoritmo ADA/EASD - December 2008 - 217 Sócios da SBD. Available at: http://www.diabetes.org.br/agenda/
comunicados/index.php?id=1838. Accessed on: July 13, 2009.
Table 2: Interpretation of acceptability levels of arguments 
based on individual scores
Score Acceptability Level Interpretation
0 - 2 1 Full rejection
3 - 4 2 Partial rejection
5 - 6 3 Neutrality
7 - 8 4 Partial acceptance
9 - 10 5 Full acceptance
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Page 3 of 9New SBD algorithm proposal for treating type 2 diabetes
The new algorithm proposal for the treatment of type 2
diabetes was developed based on the premises and assess-
ments conducted through the survey with SBD members
and the assessment of conclusions from the panel of spe-
cialists (Table 4).
The presentation format of the new algorithm proposal
was developed taking as fundamental reference the rec-
ommendations by the Joslin Diabetes Center & Joslin
Clinic and also by the American Association of Clinical
Endocrinologists [6-9]..
The present algorithm was completed before the publi-
cation of the recent AACE/ACE algorithm [10]. As
pointed out in the recent AACE algorithm safety, efficacy
and effectiveness must be the priorities and in developing
countries like Brazil cost of medications is an important
barrier and could Influence the treatment.
Module 4
Summary of therapeutic profile of drugs used for treating 
type 2 diabetes
Comparative efficacy and potential of A1C reduction of 
different therapeutic interventions
The various therapeutic interventions present different
levels of comparative efficacy and of potential of A1C
reduction. Such facts must be taken into account when
determining the best therapeutic strategy for each patient
(table 5) [11,12].
Summary of therapeutic profiles of drugs used for treating 
type 2 diabetes
The main features of therapeutic profiles of drugs used
for treating type 2 diabetes are summarized in table
6[13,14].
Fixed combinations of oral antidiabetic drugs
Due to its convenience and comparatively lower prices,
fixed-combination therapies for treating diabetes are
being made available more frequently. There are many
presentations of combined treatments, including two oral
agents in the same package, however with separate pills
(table 7) or a single pill containing both active agents in
the same formulation (table 8).
Action profile of human insulin and human insulin analogs
Basically, there are three commercial presentation forms
of insulin in the Brazilian marketplace: 1) human insulin
in monotherapy; 2) human insulin analog in monother-
apy; 3) biphasic human insulin analogs.
The addition of insulin to patients with type 2 diabetes
must be done as soon as the patient did not reach the tar-
get of HbA1c [15]. No definitve conclusions regarding the
association between insulin therapy with glargine [16]
and malignancies were established.
Table 9 summarizes the main features of the action pro-
file of insulin preparations available.
Biphasic insulin analogs have a long-acting insulin
component, in a formulation combined with a short-act-
ing insulin component, as shown in table 10
Module 5
Treatment cost estimate for various therapeutic options
The concept of Evidence-Based Medicine recognizes
three main components to help physicians define thera-
peutic conduct: the evidence of research per se, the clini-
cal expertise of physicians and patient preferences.
Treatment cost must be one of the fundamental factors
for patients to fulfill their right of choice in due propor-
tion, in the concept of evidence-based medicine [17].
We added two website suggestions for physicians to
obtain information about drug costs for consumers of the
therapeutic options they intend to prescribe. In both ref-
erences, prices are displayed in different rows expressing
the costs of each drug, considering the incidence of dis-
tinct tax rates, which vary according to Brazilian states.
Table 3: Laboratory targets for proper T2DM treatment
Parameter Laboratory Targets
Desirable Levels Tolerable Levels
Glycated hemoglobin (A1C) <7% (in adults) 7.5-8.5%: 0-6 years old1;
<8%: 6-12 years old1;
<7.5%: 13-19 years old1;
8%: in the elderly1,3
Fasting glycemia <110 mg/dL Up to 130 mg/dL2
Pre-prandial glycemia <110 mg/dL Up to 130 mg/dL2
Post-prandial glycemia <140 mg/dL Up to 180 mg/dL2
NHospitalization if glycemic 
levels >300 mg/dL
↓
L Under the following conditions:
• Diabetic ketoacidosis and hyperosmolar state
= Or =
• Intercurrent severe disease or comorbidity
↓
Start therapy according to the algorithm 
recommendations and to glycemic control 
obtained after discharge from hospital
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Table 4: Algorithm for the treatment of type 2 diabetes - 2009 update -
STAGE 1: INITIAL CONDUCT ACCORDING TO CURRENT CLINICAL CONDITIO
Mild manifestations Moderate manifestations Severe manifestations
↓ ↓ ↓
• Glycemic levels <200 mg/dL
+
• Mild symptoms or no symptoms
+
• Absence of other acute concomitant 
diseases
• Any glycemic levels between 200-300 mg/dL
+
• Absence of criteria for mild or severe 
manifestations
• Any glycemic levels above 300 mg/d
= Or =
• Significant weight loss
= Or =
• Severe and significant symptoms
= Or =
• Presence of ketonuria
↓ ↓ ↓
Metformin (500 mg/day, intensifying up to 
2,000 mg/day) + lifestyle changes.
If patient does not reach A1C<7%
in 4-6 weeks → 
Note: In case of metformin intolerance, 
prolonged action formulations may be 
useful. If the problem persists, choose one of 
the options in Step 2
Metformin (500 mg/day, intensifying up to
2,000 mg/day) +
lifestyle changes + other oral antidiabetic drugs
CRITERIA FOR INCLUDING SECOND OAD
↓
Start insulin therapy immediately
STAGE 2: ADD OR MODIFY SECOND AGENT ACCORDING TO A1C LEVEL(*
7- 8% 8-10% >10%
Sulphonylurea
DPP-4 inhibitors
Glitazone
Glinides (prevalent post-prandial 
hyperglycemia)
Acarbose (prevalent post-prandial 
hyperglycemia)
Exenatide (overweight or obesity)
Sulphonylurea
DPP-4 inhibitors
Glitazone
Basal insulin (bedtime)
Exenatide (overweight or obesity)
Insulin therapy
Basal insulin + prandial insulin
With of without
Metformin
Sulphonylurea
iDPP-4 (studies currently being made
 in table 7.
 GOALS: A1C<7%, FASTING GLYCEMIA <130 mg/dL OR 
↓
<7%, fasting glycemia<130 mg/dL or post-prandial 
 are reached.
ns for each clinical situation. The choice of the best L
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(*) In order to select the second agent, we suggest looking at therapeutic drug profiles
MONITORING AND ADJUSTMENTS IN TREATMENT AFTER 2-3 MONTHS WITH MAXIMUM EFFECTIVE DOSAGE IN ORDER TO REACH
POST-PRANDIAL GLYCEMIA (2 HOURS) <180 mg/dL
STAGE 3: ADD A THIRD ORAL AGENT OR INTENSIFY INSULIN TREATMENT
↓
Add a third oral agent with a different action mechanism. If in 2 or 3 months the targets of 
A1C<7%, fasting glycemia <130 mg/dL or post-prandial glycemia (2 hours) <180 mg/dL are not 
reached, start insulin therapy.
→
Intensify insulin therapy until the A1C
glycemia (2 hours) <180 mg/dL goals
INSTRUCTIONS AND ADDITIONAL COMMENTS
1.Similarly to any other Guideline, this Algorithm contains general recommendations about the most highly indicated therapeutic optio
therapeutical plan must be made based on medical judgment, in patient's options and in treatment costs with the respective drugs.
2.For further information on the potential of A1C level reduction of different drugs, please refer to table 6, in Module 4.
3.For further summarized information on therapeutic and usage safety profile of several drugs, please refer to table 7, in Module 4.
Abbreviations:
A1C = glycated hemoglobin; inhibitors ofDPP-4 (dipeptidyl peptidase-4 ); OAD = oral antidiabetic drugs.
Table 4: Algorithm for the treatment of type 2 diabetes - 2009 update - (Continued)
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Page 6 of 9For the physician, the desired piece of information is the
maximum retail price (MRP), which may be found in the
last row to the right in price tables.
Links to browse drug prices
http://portal2.saude.gov.br/BPS/visao/consultapublica/
publico_interno_item.cfm[18]
Using the internal resource of research to obtain the
desired price http://www.elomedico.com.br[19]
Requires previous and free subscription. Search for
item "drugs/prices" on the left row in the homepage
Table 5: Comparative efficacy of therapeutic interventions for reducing A1C levels
Strategy/Drug Expected Reduction in A1C (%)
Weight reduction and increase in physical activity 1.0 - 2.0
Metformin 1.0 - 2.0
Insulin as additional therapy 1.5 - 3.5
Sulfonylurea 1.0 - 2.0
Glitazones 0.5 - 1.4
GLP1 Agonists 0.5 - 1.0
DPP-4 Inhibitors 0.5 - 0.8
Alpha-glycosidase Inhibitors 0.5 - 0.8
Glinides 0.5 - 1.5
Table 6: Pharmacologic options for oral DM-2 treatment
DRUG PROFILE AND ACTION MECHANISM
Acarbose (Glucobay®) Slows down intestinal glucose absorption. Low potential of A1C reduction (0.5 - 0.8%). 
Gastrointestinal intolerance.
Metformin (Glifage®, others) Reduces primarily the hepatic glucose production and fights insulin resistance. High potential of 
A1C reduction (2%). Gastrointestinal intolerance. Does not cause hypoglycemia. May promote mild 
weight loss. Contraindicated in case of renal dysfunction.
Glitazones
- Rosiglitazone (Avandia®)
- Pioglitazone (Actos®)
Primarily fight insulin resistance and reduces hepatic glucose production. Increases muscle, fatty 
tissue and liver sensitivity to insulin. Intermediate A1C reduction potential (0.5 - 1.4%). Promote 
hydric retention and weight gain, increasing the risk of heart failure. Also increase the risk of 
fracture. Recent results of studies such as RECORD and BARI 2D indicate that rosiglitazone does not 
increase the risk of infarction and CVD.
Sulfonylureas
- Glimepiride (Amaryl®)
- Glibenclamide (Daonil®)
- Gliclazide (Diamicron MR®)
- Others
Stimulate endogenous insulin production by pancreatic beta cells, with pharmacological action 
medium to long (8-24 hours). Useful to control fasting glycemia and 24-hour glycemia. High 
potential of A1C reduction (2%). May cause hypoglycemia. Glibenclamide has higher risk of 
hypoglycemia. An alleged deleterious action on human beta cells has not yet been confirmed.
Glinides
- Repaglinide (Novonorm®, 
Prandin®)
- Nateglinide (Starlix®)
Stimulate endogenous insulin production by pancreatic beta cells, with short duration (1-3 hours). 
Useful to control post-prandial hyperglycemia. Intermediate potential of A1C reduction (1.0 - 
1.5%). May promote weight gain and hypoglycemia. Repaglinide is more powerful than 
nateglinide.
Incretin mimetics and DPP-4 
inhibitors
- Exenatide (Byetta®)
- Vildagliptin (Galvus®)
- Sitagliptin (Januvia®)
This is a new therapeutic class for treating diabetes, whose mechanism includes stimulating beta 
cells to increase insulin synthesis and action on pancreatic alpha cells, reducing glucagon 
production. Glucagon has the effect of increasing glycemic levels. Average potential of A1C 
reduction (0.5 - 0.8%, depending on the basal A1C value). Do not cause hypoglycemia but 
gastrointestinal intolerance and pancreatitis have been described (exenatide and sitaglipitn) 
[13,14].
This table represents only a partial relation of commercial medications of various drugs and does not represent a specific recommendation of 
any commercial brand.
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Table 8: Partial relation of oral antidiabetic drugs at combination therapy: two substances in a single pill
Therapeutic classes Chemical Denomination Commercial Denomination Action and Dosage Mechanism
biguanide
+
sulphonylurea
metformin
+
glibenclamide
Glucovance®
Merck
Peripheral action insulin sensitizer 
(metformin) + long-acting secretagogue of 
insulin (glibenclamide).
Dosage:
250 mg metformin+1.25 mg glibenclamide 
500 mg metformin + 2.5 mg glibenclamide 
500 mg metformin + 5 mg glibenclamide.
glitazone
+
biguanides
rosiglitazone
+
metformin
Avandamet®
Glaxo
Combination of two peripheral action insulin 
sensitizers, with different action
Dosage:
2 mg rosiglitazone + 500 mg metformin
4 mg rosiglitazone + 500 mg metformin.
Incretin mimetic
+
metformin
sitagliptin
+
metformin
Janumet®
MSD
DPP-4inhibitor + peripheral action insulin 
sensitizer (metformin).
Dosage:
50 mg sitagliptin + 500,
850 or 1,000 mg metformin
Incretin mimetic
+
metformin
vildagliptin
+
metformin
Galvus Met®
Novartis
DPP-4 inhibitor + peripheral action insulin 
sensitizer (metformin).
Dosage:
50 mg vildagliptin +
500, 850 or 1,000 mg metformin
This table presents only a partial list of commercial medications of various drugs and does not represent a specific recommendation of any 
commercial brand.
Table 7: Partial list of oral antidiabetic drugs used in combination therapy: two substances in separate pills
Therapeutic classes Chemical Denomination Commercial Denomination Action and Dosage Mechanism
sulffonylurea
+
biguanide
glimepiride
+
metformin
Amaryl Flex®
Sanofi-Aventis
Long acting secretagogue of insulin 
(glimepiride) + peripheral action insulin 
sensitizer (metformin).
Dosage: glimepiride - 1 mg and 2 mg + 
metformin - 500 mg.
glinide
+
biguanide
nateglinide
+
metformin
Starform®
Novartis
Short-acting secretagogue of insulin 
(nateglinide) + peripheral action insulin 
sensitizer (metformin).
Dosage: nateglinide - 120 mg + metformin - 
500 mg and 850 mg.
This table presents only a partial list of commercial medications of various drugs and does not represent a specific recommendation of any 
commercial brand.
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Page 8 of 9Table 9: action profile of human insulin and human insulin analogs
Human
Insulins
Insulin Type Onset Action peak Duration of action
Rapid-acting insulin analogs Glulisine
(Apidra®)
<5-15 minutes 1 hour 4 hours
Lispro
(Humalog®)
<15 minutes 0.5-1.5 hour 2-4 hours
Aspart
(NovoRapid®)
5-10 minutes 1-3 hours 3-5 hours
Short acting insulin Regular
(Novolin® R, Humulin® R)
30-60 minutes 2-3 hours 3-6 hours
Intermediate acting insulin NPH (Novolin® N Humulin® N) 2-4 hours 4-10 hours 10-16 hours
Long-acting insulin analogs Glargine
(Lantus®)
1-2 hours None Up to 24 hours
Detemir
(Levemir®)
1-2 hours None Up to 24 hours
This table presents only a partial list of commercial medications of various drugs and does not represent a specific recommendation of any 
commercial brand.
Table 10: Biphasic rapid and long-acting insulin analogs
Insulin aspart and protaminated (70%) + insulin 
aspart (30%)
NovoMix® 70/30 Pre-mix with 70% long-acting insulin aspart (up to 24 hours) 
+ 30% aspart insulin of immediate release, short acting (4-6 
hours), to control post-prandial and interprandial glycemic 
levels
Neutral protamine insulin lispro (75%) + insulin 
lispro (25%)
Humalog® Mix
25
Pre-mix with 75% intermediate acting insulin NPL (up to 24 
hours) + 25% insulin of immediate release, short-acting (4-5 
hours), to control post-prandial and interprandial glycemic 
levels
Neutral protamine insulin lispro (50%) + insulin 
lispro (50%)
Humalog® Mix
50
Pre-mix with 50% intermediate acting insulin NPL (up to 24 
hours) + 50% insulin of immediate release, short-acting (4-5 
hours), to control post-prandial and interprandial glycemic 
levels
This table presents only a partial list of commercial medications of various drugs and does not represent a specific recommendation of any 
commercial brand.
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